Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year […]
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Free Report) was the target of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 17,600,000 shares, an increase of 21.1% from the September 15th total of 14,530,000 shares. Based on an average daily volume of 2,870,000 shares, […]
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Free Report) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 14,530,000 shares, a decline of 7.2% from the August 31st total of 15,650,000 shares. Based on an average daily volume of 2,990,000 shares, the days-to-cover ratio […]
HC Wainwright restated their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS – Free Report) in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a $20.00 price objective on the biotechnology company’s stock. Several other analysts also recently issued reports on the company. Citigroup started coverage on Coherus BioSciences in a […]